Myxoid dermatofibrosarcoma protuberans of the vulva in a postnatal woman: a case report

Background: Vulval Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous sarcoma that develops from the dermis, with less than 70 reported cases. This case discusses a holistic approach to vulval DFSP in a postpartum woman—with the balance of surgical excision against functional, psychosexual and cosmetic outcomes. Case: A 24-year-old woman noticed a rapidly enlarging vulval mass during pregnancy, which was an 8 cm left sided vulval mass which stretched from the periclitoral area to the inguinal crease. A core biopsy showed an indeterminate low grade myxoid lesion. Magnetic Resonance Imaging (MRI) reported no local metastasis or fascial involvement and Positron Emission Tomography (PET) and Computed Tomography (CT) scan showed metabolically active soft tissue mass without distant metastasis. Postpartum, she was referred to a Gynaecological Oncologist at a tertiary centre where it was discussed with Sarcoma and Plastic Surgeons. A radical local excision of vulvar mass, mesh reconstruction of rectus sheath and left inguinal ligaments and superficial circumflex iliac perforator flap of the left thigh was performed. Initial histopathology exhibited a myxoid lesion with negative staining including CD34, which is characteristic for DFSP. Due to indeterminate histopathology, RNA-sequencing was used and showed disease-defining chromosomal fusion (COL1A1::PDGFB fusion), which assisted the diagnosis, as this is present in over 90% of tumours. The tumour was excised over 10 mm laterally and 5 mm deep. Conclusions: Over 70% of DFSP is positive for CD34 and this shows the importance of RNA-sequencing in cases of indeterminate histology. Due to high recurrence, guidelines have suggested lateral margins from 10 mm up to 30 mm. Though, in a young woman this was considered against long-term sexual and functional outcomes. She will undergo close surveillance both clinically and with MRI.

Dermatofibrosarcoma protuberans; DFSP; Postnatal; Sarcoma; Vulva; Myxoid

[1] Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000; 88: 2711–2720.

[2] Wiszniewska J, Roy A, Masand RP. Myxoid dermatofibrosarcoma protuberans of the vulva: case report of a rare variant in an unusual location, with unusual morphologic and immunohistochemical feature. American Journal of Dermatopathology. 2016; 38: 226–230.

[3] Kreicher KL, Kurlander DE, Gittleman HR, Barnholtz-Sloan JS, Bordeaux JS. Incidence and survival of primary dermatofibrosarcoma protuberans in the United States. Dermatologic Surgery. 2016; 42: S24–S31.

[4] Mancari R, Cioffi R, Magazzino F, Attademo L, Sant’angelo M, Taccagni G, et al. Dermatofibrosarcoma protuberans of the vulva: a review of the MITO rare cancer group. Cancers. 2024; 16: 222.

[5] NCCN. Soft tissue sarcoma guidelines. 2024. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464 (Accessed: 27 February 2025).

[6] Thway K, Noujaim J, Jones RL, Fisher C. Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. Annals of Diagnostic Pathology. 2016; 25: 64–71.

[7] Vathiotis IA, Psichogiou E, Syrigos KN, Kotteas EA. Lung metastasis from fibrosarcomatous dermatofibrosarcoma protuberans of the vulva: a rare case report. Journal of Lower Genital Tract Disease. 2018; 22: 85–87.

[8] Nguyen AH, Detty SQ, Gonzaga MI, Huerter C. Clinical features and treatment of dermatofibrosarcoma protuberans affecting the vulva: a literature review. Dermatologic Surgery. 2017; 43: 771–774.

[9] Kibbi N, Wang D, Wang WL, Galan A, Leffell DJ, Christensen SR, et al. Dermatofibrosarcoma protuberans in pregnancy: a case series and review of the literature. International Journal of Dermatology. 2021; 60: 1114–1119.

[10] Jahanseir K, Xing D, Greipp PT, Sukov WR, Keeney GL, Howitt BE, et al. PDGFB rearrangements in dermatofibrosarcoma protuberans of the vulva: a study of 11 cases including myxoid and fibrosarcomatous variants. International Journal of Gynecological Pathology. 2018; 37: 537–546.

[11] Salgado R, Llombart B, M Pujol R, Fernández-Serra A, Sanmartín O, Toll A, et al. Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization methodologies. Genes, Chromosomes & Cancer. 2011; 50: 510—517.

[12] Jozwik M, Bednarczuk K, Osierda Z. Dermatofibrosarcoma protuberans: an updated review of the literature. Cancers. 2024; 16: 3124.

[13] Saiag P, Grob JJ, Lebbe C, Mavehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. European Journal of Cancer. 2015; 51: 2604–2608.

[14] Song C, Bhogesha S, Chu S, Song C. Review of the superficial circumflex iliac artery perforator flap: recommendations to the approach of a groin perforator flap. Australasian Journal of Plastic Surgery. 2020; 3: 20–29.

[15] Rutkowski P, Debiec-Rychter M. Current treatment options for dermatofibrosarcoma protuberans. Expert Review of Anticancer Therapy. 2015; 15: 901–909.

[16] Miller SJ, Alam M, Andersen JS, Berg D, Bichajikin CK, Bowen GM, et al. Dermatofibrosarcoma protuberans. Journal of the National Comprehensive Cancer Network. 2012; 10: 312–318.